The FTSE 100 pharma company, Shire, says the US Food and Drug Administration has approved a rival's application to make a generic version of an attention deficit and hyperactivity disorder (ADHD) drug.
Actavis has been given the all clear to manufacture a generic form of Adderall XR.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Accelerating state pension age hikes could cost Brits in early 50s almost £18,000A recently launched review of the state pension age has sparked concern that the planned increases could be accelerated. How much could it cost you?
-
How to invest according to your age - the one rule everyone can followWhether you’re a seasoned investor or new to the game, here’s the one investing rule to help determine how much you should invest according to your age
